Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia

Schizophrenia Research

Volumn 86, Issue 1-3, 2006, Pages 30-35

  Fan, Xiaoduo ^a,b   Liu, Emily ^c,d   Pristach, Cynthia ^d,e   Goff, Donald C ^a,b   Henderson, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CHILDREN S HOSPITAL OF BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

Insulin; Psychopathology; Schizophrenia

Indexed keywords

GLUCOSE; INSULIN; LIPID;

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; LIPID BLOOD LEVEL; MALE; MENTAL DISEASE; NEUROPATHOLOGY; ONSET AGE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPATHOLOGY; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33747167342     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.04.010     Document Type: Article

References (36)

1. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., and Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29 (2004) 1326-1334
2. Biessels G.J., Kamal A., Urban I.J., Spruijt B.M., Erkelens D.W., and Gispen W.H. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 800 (1998) 125-135
3. Birch N.P., Christie D.L., and Renwick A.G. Immunoreactive insulin from mouse brain cells in culture and whole rat brain. Biochem. J. 218 (1984) 19-27
4. Boyd Jr. F.T., Clarke D.W., Muther T.F., and Raizada M.K. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. J. Biol. Chem. 260 (1985) 15880-15884
5. Craft S., Asthana S., Newcomer J.W., Wilkinson C.W., Matos I.T., Baker L.D., Cherrier M., Lofgreen C., Latendresse S., Petrova A., Plymate S., Raskind M., Grimwood K., and Veith R.C. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 56 (1999) 1135-1140
6. Czobor P., Volavka J., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Cooper T.B., Chakos M., and Lieberman J.A. Antipsychotic-induced weight gain and therapeutic response: a differential association. J. Clin. Psychopharmacol. 22 (2002) 244-251
7. Devaskar S.U., Giddings S.J., Rajakumar P.A., Carnaghi L.R., Menon R.K., and Zahm D.S. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 269 (1994) 8445-8454
8. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., and Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26 (2000) 903-912
9. Ebenbichler C.F., Laimer M., Eder U., Mangweth B., Weiss E., Hofer A., Hummer M., Kemmler G., Lechleitner M., Patsch J.R., and Fleischhacker W.W. Olanzapine induces insulin resistance: results from a prospective study. J. Clin. Psychiatry 64 (2003) 1436-1439
10. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
11. Fujisawa Y., Sasaki K., and Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol. Psychiatry 30 (1991) 1219-1228
12. Harrison G., Croudace T., Mason P., Glazebrook C., and Medley I. Predicting the long-term outcome of schizophrenia. Psychol. Med. 26 (1996) 697-705
13. Havrankova J., Roth J., and Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272 (1978) 827-829
14. Heiskanen T., Niskanen L., Lyytikainen R., Saarinen P.I., and Hintikka J. Metabolic syndrome in patients with schizophrenia. J. Clin. Psychiatry 64 (2003) 575-579
15. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., Weber M.T., Anderson E.J., Allison D.B., Daley T.B., Schoenfeld D., and Goff D.C. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62 (2005) 19-28
16. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
17. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., and Fehm H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74 (2001) 270-280
18. Lamberti J.S., Bellnier T., and Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am. J. Psychiatry 149 (1992) 689-690
19. Lane H.Y., Chang Y.C., Cheng Y.C., Liu G.C., Lin X.R., and Chang W.H. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J. Clin. Psychiatry 64 (2003) 316-320
20. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., and Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry 149 (1992) 68-72
21. Lozovsky D.B., Kopin I.J., and Saller C.F. Modulation of dopamine receptor supersensitivity by chronic insulin: implication in schizophrenia. Brain Res. 343 (1985) 190-193
22. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., and Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
23. McGlashan T.H. The prediction of outcome in chronic schizophrenia. IV. The Chestnut Lodge follow-up study. Arch. Gen. Psychiatry 43 (1986) 167-176
24. Melkersson K.I., Hulting A.L., and Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry 61 (2000) 742-749
25. Meltzer H.Y., Perry E., and Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr. Res. 59 (2003) 19-27
26. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., Patel J.K., Keefe R.S., Stroup T.S., and Lieberman J.A. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 80 (2005) 9-18
27. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. 163 (2003) 427-436
28. Planansky K., and Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J. Clin. Exp. Psychopathol. 20 (1959) 53-57
29. Saari K.M., Lindeman S.M., Viilo K.M., Isohanni M.K., Jarvelin M.R., Lauren L.H., Savolainen M.J., and Koponen H.J. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry 66 (2005) 559-563
30. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 (2002) 561-566
31. Singh M.M., De Dios L.V., and Kline N.S. Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 11 (1970) 562-570
32. Unger J., McNeill T.H., Moxley R.T., White M., Moss A., and Livingston J.N. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 31 (1989) 143-157
33. Wan Q., Xiong Z.G., Man H.Y., Ackerley C.A., Braunton J., Lu W.Y., Becker L.E., MacDonald J.F., and Wang Y.T. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 388 (1997) 686-690
34. Warnick G.R. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 129 (1986) 101-123
35. Woods S.C., Porte Jr. D., Bobbioni E., Ionescu E., Sauter J.F., Rohner-Jeanrenaud F., and Jeanrenaud B. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. Am. J. Clin. Nutr. 42 (1985) 1063-1071
36. Zhao W.Q., and Alkon D.L. Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 177 (2001) 125-134